Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis.
Kako S, Fujiwara S, Sato M, Kimura SI, Nakasone H, Ohashi K, Kawakita T, Maeda T, Morishita T, Suzuki R, Fukuda T, Ichinohe T, Kurata M, Atsuta Y, Kanda Y. Kako S, et al. Among authors: fujiwara s. Biol Blood Marrow Transplant. 2018 Oct;24(10):2139-2144. doi: 10.1016/j.bbmt.2018.04.015. Epub 2018 Apr 19. Biol Blood Marrow Transplant. 2018. PMID: 29680515 Free article. Clinical Trial.
[Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M, Muroi K, Matsuyama T, Oka S, Ono Y, Yamamoto C, Uesawa M, Okabe H, Matsu H, Tatara R, Kikuchi Y, Fujiwara S, Kikuchi S, Sato K, Ueda M, Toshima M, Ozaki K, Takatoku M, Nagai T, Ozawa K. Mori M, et al. Among authors: fujiwara s. Rinsho Ketsueki. 2007 Aug;48(8):624-31. Rinsho Ketsueki. 2007. PMID: 17867298 Japanese.
The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
Nakano H, Fujiwara SI, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Nakano H, et al. Among authors: fujiwara si. Hematol Oncol. 2017 Sep;35(3):357-364. doi: 10.1002/hon.2277. Epub 2015 Dec 7. Hematol Oncol. 2017. PMID: 26639319
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Minakata D, et al. Among authors: fujiwara s. Leuk Res. 2016 Mar;42:82-7. doi: 10.1016/j.leukres.2015.12.013. Epub 2016 Jan 2. Leuk Res. 2016. PMID: 26790727
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara S, Ohmine K, Suzuki T, Muroi K, Kanda Y. Yamamoto C, et al. Among authors: fujiwara s. Leuk Lymphoma. 2016 Nov;57(11):2541-7. doi: 10.3109/10428194.2016.1153087. Epub 2016 Feb 25. Leuk Lymphoma. 2016. PMID: 26917050
Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. Umino K, et al. Among authors: fujiwara si. Leuk Lymphoma. 2017 Feb;58(2):316-323. doi: 10.1080/10428194.2016.1190975. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27267694
2,421 results